Berdazimer Topical Gel, 10.3%: First Approval

<div><strong>Declarations</strong></div> <div><strong>Funding</strong> The preparation of this review was not supported by any external funding.</div> <div><strong>Authorship and Conflict of interest</strong> During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.</div> <div><strong>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</strong> Not applicable.</div> <div>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank"><strong>here</strong></a>.</div> <p><br></p> <div><strong>Abstract</strong></div> <p>Berdazimer topical gel, 10.3% (ZELSUVMI™) is a nitric oxide (NO)  releasing topical gel developed by Novan Inc. (a Ligand Pharmaceuticals company) for the treatment of molluscum contagiosum (MC). Novan has used their proprietary NO-based technology platform (NITRICIL™), which stores gaseous NO species on large polymers, in the development of berdazimer topical gel, 10.3%.  In January 2024, berdazimer topical gel, 10.3% was approved for the topical treatment of MC in adult and paediatric patients 1 year of age and older in the USA. This article summarizes the milestones in the development of berdazimer topical gel, 10.3%  leading to this first approval for the treatment of MC.</p> <p>© Springer Nature Switzerland AG 2024</p>